Article
Pharmacology & Pharmacy
Stella Trompet, Iris Postmus, Helen R. Warren, Raymond Noordam, Roelof A. J. Smit, Elizabeth Theusch, Xiaohui Li, Benoit Arsenault, Daniel I. Chasman, Graham A. Hitman, Patricia B. Munroe, Jerome I. Rotter, Bruce M. Psaty, Mark J. Caulfield, Ron M. Krauss, Adrienne L. Cupples, Wouter J. Jukema
Summary: The pharmacogenetic effect of genetic variation on cardiovascular disease risk reduction in response to statin treatment was investigated through a genome-wide association study (GWAS). The results showed that genetic variation did not significantly affect the response of statins on cardiovascular risk reduction. This suggests that genetic testing for predicting the effects of statins on clinical events may not be a useful tool in clinical practice.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, Research & Experimental
Rafal Swiechowski, Agnieszka Jelen, Jacek Pietrzak, Piotr Galecki, Dagmara Szmajda-Krygier, Ewa Balcerczak
Summary: The study found that the CYP3A5*3 allele may have a protective role in the development of depression, while patients with at least one CYP2C19*2 allele showed better treatment outcomes. The different allelic variants of these cytochromes have some impact on the onset and therapeutic effectiveness of depression in patients.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Immunology
William T. Connell, Julie Hong, Wilson Liao
Summary: Genetic factors, including rs35569429 and HLA-C*06:02, are associated with the response to ustekinumab therapy in psoriasis. The presence of the deletion allele of rs35569429 and being HLA-C*06:02 negative are associated with a lower treatment response rate.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Pharmacology & Pharmacy
Evangelia Eirini Tsermpini, Sara Redensek, Vita Dolzan
Summary: This article reviews the impact of genetic variations on the occurrence of tardive dyskinesia (TD) in experimental animal models and clinical studies. Eight genes have been identified from preclinical findings that have also reached statistical significance in at least one clinical study. However, the results of clinical studies are often conflicting and not conclusive enough to support their implementation in clinical practice.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Clinical Neurology
Caty Carrera, Jara Carcel-Marquez, Natalia Cullell, Nuria Torres-Aguila, Elena Muino, Jose Castillo, Tomas Sobrino, Francisco Campos, Emilio Rodriguez-Castro, Laia Llucia-Carol, Monica Millan, Lucia Munoz-Narbona, Elena Lopez-Cancio, Alejandro Bustamante, Marc Ribo, Jose Alvarez-Sabin, Jordi Jimenez-Conde, Jaume Roquer, Eva Giralt-Steinhauer, Carolina Soriano-Tarraga, Marina Mola-Caminal, Cristofol Vives-Bauza, Rosa Diaz Navarro, Silvia Tur, Victor Obach, Juan Francisco Arenillas, Tomas Segura, Gemma Serrano-Heras, Joan Marti-Fabregas, Raquel Delgado-Mederos, M. Mar Freijo-Guerrero, Francisco Moniche, Juan Antonio Cabezas, Mar Castellanos, Cristina Gallego-Fabrega, Jonathan Gonzalez-Sanchez, Jurek Krupinsky, Daniel Strbian, Turgut Tatlisumak, Vincent Thijs, Robin Lemmens, Agnieszka Slowik, Johanna Pera, Steven Kittner, John Cole, Laura Heitsch, Laura Ibanez, Carlos Cruchaga, Jin-Moo Lee, Joan Montaner, Israel Fernandez-Cadenas
Summary: The study identified single nucleotide variants in the ZBTB46 gene that are associated with a higher risk of parenchymal haematoma following recombinant tissue-plasminogen activator treatment.
Article
Clinical Neurology
Christine M. Ramsey, Kevin G. Lynch, Michael E. Thase, Joel Gelernter, Henry R. Kranzler, Jeffrey M. Pyne, Mei-Chiung Shih, Annjannette Stone, David W. Oslin
Summary: The study investigates the use of pharmacogenetics in patients with Major Depressive Disorder and finds that PGx testing may result in clinically significant gene-drug interactions for 20% of patients prescribed antidepressants. Patients with prior antidepressant treatment are more likely to have significant gene-drug interactions in their next intended treatment, suggesting they may benefit most from PGx testing.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Review
Pharmacology & Pharmacy
Malgorzata Borczyk, Marcin Piechota, Jan Rodriguez Parkitna, Michal Korostynski
Summary: This article discusses the variability of antidepressant effectiveness in treating major depressive disorder among patients, with genetic factors playing a significant role in individual responses. The integration of genomics and pharmacology can provide guidance for personalized treatment of depression.
BRITISH JOURNAL OF PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Claudia Pisanu, Anna Meloni, Giovanni Severino, Alessio Squassina
Summary: This article provides an overview of the most relevant findings regarding the pharmacogenomics and pharmacoepigenomics of lithium response in bipolar disorder. It discusses the candidate gene studies, genome-wide association studies, and post-GWAS approaches that support an association between genetic load for various psychiatric disorders and poor response to lithium. The article also explores the role of epigenetic mechanisms, such as changes in methylation or noncoding RNA levels, in regulating gene expression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Genetics & Heredity
Milica Radosavljevic, Dubravka Svob Strac, Jasna Jancic, Janko Samardzic
Summary: Pharmacotherapy for neuropsychiatric disorders, such as anxiety and depression, is highly variable among individuals and often results in side effects. Pharmacogenetics, as a part of personalized medicine, aims to optimize therapy by targeting genetic variations involved in drug metabolism and efficacy. Recent studies have shown that genotype-guided decisions can improve the effectiveness and safety of antidepressant and anxiolytic treatments. Additionally, the emerging field of pharmacoepigenetics investigates how epigenetic mechanisms may influence individual drug responses. Understanding the epigenetic variability of patients' response to pharmacotherapy can lead to the selection of more effective drugs and minimize adverse reactions, ultimately improving treatment outcomes.
Review
Neurosciences
Zack Blumenfeld, Kallol Bera, Eero Castren, Henry A. Lester
Summary: This article summarizes the therapeutic actions of antidepressants when they encounter their targets inside cells or intracellular organelles. It discusses the chemical, pharmacokinetic, and pharmacodynamic principles underlying drug movements into subcellular compartments. The article highlights the importance of charge and hydrophobicity/lipid solubility in drug membrane permeation and provides data and calculations for various antidepressants regarding their structures, charge properties, and distribution volume. It also reviews the pharmacokinetics of ketamine, ketamine metabolites, and other rapidly acting antidepressants, as well as the mechanisms involving intracellular targets.
NEUROPSYCHOPHARMACOLOGY
(2023)
Review
Chemistry, Medicinal
Atefeh Jalali, Negar Firouzabadi, Mohammad M. Zarshenas
Summary: Depression is a common mental disorder worldwide, with genetic factors and bioactive compounds in medicinal plants being linked to its treatment outcomes. Traditional Persian medicine manuscripts provide various anti-depressant remedies, which may offer new insights into depression prevention and management when combined with genetics science.
PHYTOTHERAPY RESEARCH
(2021)
Article
Clinical Neurology
Chiara Fabbri, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Diego Albani, Gianluigi Forloni, Panagiotis Ferentinos, Dan Rujescu, Julien Mendlewicz, Diana De Ronchi, Marco Andrea Riva, Cathryn M. Lewis, Alessandro Serretti
Summary: This study aimed to identify new potential treatments for treatment-resistant depression (TRD) by analyzing genes and drug databases, discovering some promising drug targets including known drugs for TRD, as well as novel molecules and antioxidant polyphenols nutraceuticals.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2021)
Article
Psychiatry
Zihao Liang, Jinyun Song, Shuanglin Gu, Xiuzhen Chen, Yonglin Li, Hongyu Zhao
Summary: This study used Mendelian randomization (MR) to investigate the relationship between depression, anxiety, and COVID-19 infection. The findings suggest that anxiety is a risk factor for severe symptoms following COVID-19 infection, but there is no causal effect of depression and anxiety on COVID-19 infection.
FRONTIERS IN PSYCHIATRY
(2023)
Article
Genetics & Heredity
Daria Pinakhina, Danat Yermakovich, Ekaterina Vergasova, Evgeny Kasyanov, Grigory Rukavishnikov, Valeriia Rezapova, Nikita Kolosov, Alexey Sergushichev, Iaroslav Popov, Elena Kovalenko, Anna Ilinskaya, Anna Kim, Nikolay Plotnikov, Valery Ilinsky, Nikholay Neznanov, Galina Mazo, Alexander Kibitov, Alexander Rakitko, Mykyta Artomov
Summary: We conducted a genome-wide association study on individuals of Russian descent and identified a novel association at the chromosome 7q21 locus in depression. Gene prioritization analysis suggested that MAGI2 (S-SCAM) is the most likely gene and a potential susceptibility gene for depression based on existing knowledge of depression risk genes. The expression patterns in the brain and gut highlighted the functional relationship between MAGI2 and previously known depression risk genes. Local genetic covariance analysis provided initial evidence of a different relationship between the scales of hospital anxiety and depression and the disturbance in the gut-brain axis.
FRONTIERS IN GENETICS
(2023)
Article
Oncology
Guang-Li Zhu, Cheng Xu, Kai-Bin Yang, Si-Qi Tang, Ling-Long Tang, Lei Chen, Wen-Fei Li, Yan-Ping Mao, Jun Ma
Summary: This study suggests a causative effect of genetically predicted depression on specific types of cancer, particularly breast cancer. These findings emphasize the importance of depression in the prevention and treatment of breast cancer.
